CASI Pharmaceuticals (CASI) Other financing activities (2022 - 2025)
Historic Other financing activities for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to $715.7 million.
- Pharmaceuticals' Other financing activities fell 9989.77% to $715.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $715.7 million, marking a year-over-year decrease of 9989.77%. This contributed to the annual value of $713.3 million for FY2024, which is 9989.75% down from last year.
- As of Q2 2025, Pharmaceuticals' Other financing activities stood at $715.7 million, which was down 9989.77% from $714.6 billion recorded in Q1 2025.
- In the past 5 years, Pharmaceuticals' Other financing activities registered a high of $714.6 billion during Q1 2025, and its lowest value of $691.8 million during Q4 2022.
- For the 4-year period, Pharmaceuticals' Other financing activities averaged around $351.0 billion, with its median value being $348.0 billion (2023).
- Within the past 5 years, the most significant YoY rise in Pharmaceuticals' Other financing activities was 10249375.55% (2025), while the steepest drop was 9989.77% (2025).
- Pharmaceuticals' Other financing activities (Quarter) stood at $691.8 million in 2022, then skyrocketed by 100480.98% to $695.8 billion in 2023, then tumbled by 99.9% to $713.3 million in 2024, then rose by 0.34% to $715.7 million in 2025.
- Its last three reported values are $715.7 million in Q2 2025, $714.6 billion for Q1 2025, and $713.3 million during Q4 2024.